Edition:
United Kingdom

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

29.22USD
19 Sep 2018
Change (% chg)

$0.26 (+0.90%)
Prev Close
$28.96
Open
$28.90
Day's High
$29.31
Day's Low
$28.90
Volume
92,607
Avg. Vol
145,150
52-wk High
$32.99
52-wk Low
$20.16

Chart for

About

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $948.89
Shares Outstanding(Mil.): 38.39
Dividend: --
Yield (%): --

Financials

  RTRX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.86 -- --
ROI: -15.89 1.78 14.61
ROE: -22.95 3.29 16.33

BRIEF-Retrophin Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S

01 May 2018

BRIEF-Retrophin Initiates Pivotal Phase 3 Clinical Trial Of Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis

* RETROPHIN INITIATES PIVOTAL PHASE 3 CLINICAL TRIAL OF SPARSENTAN FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS Source text for Eikon: Further company coverage:

03 Apr 2018

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

* LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​

22 Mar 2018

Earnings vs. Estimates